Overview:
Low-grade serous ovarian cancer (LGSOC) is a rare, distinct subtype of epithelial ovarian cancer that disproportionately affects younger women and remains challenging to treat due to its slow progression, high recurrence risk, and limited responsiveness to chemotherapy. With the rapidly evolving landscape of targeted therapies—including recent advances in RAF/MEK pathway inhibitors—clinicians face increasing complexity in diagnosis, molecular interpretation, and treatment selection, highlighting a significant unmet educational need.
To address these gaps, this program will use the Cases and
Conversations™ format to deliver an interactive, case-based discussion led by
expert faculty. Presented adjunct to the 2026 SGO Annual Meeting on Women’s
Cancer in San Juan, this hybrid symposium provides an ideal forum for
translating new clinical trial data, molecular insights, and evolving standards
of care into real-world practice. The format is designed to help clinicians
contextualize emerging evidence, compare decision-making with peers and experts,
and strengthen their ability to personalize therapy for patients with LGSOC.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe key distinguishing features of low-grade serous ovarian cancer (LGOS) to ensure accurate diagnosis
- Examine the current standard of care for LGSOC, focusing on the roles of surgery and adjuvant systemic therapies, including chemotherapy, targeted therapies, and hormonal therapies
- Develop personalized treatment plans for patients with recurrent LGSOC based on patient- and disease-specific characteristics